{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:51:24Z","timestamp":1790196684496,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","funder":[{"name":"J. Arch McNamara Fund"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To investigate the incidence of ocular hypertension (OHT) after suprachoroidal injection of triamcinolone acetonide (SCS-TA) for noninfectious uveitic macular edema.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Retrospective review of eyes undergoing SCS-TA. The primary outcome was incidence of OHT (intraocular pressure [IOP] &gt; 24 mmHg). Secondary outcomes included incidence of IOP &gt; 30 mmHg, IOP rise \u226510 mmHg above baseline, and treatment for OHT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Seventy-six eyes of 70 patients were treated with a mean of 1.71 (range 1\u20135) SCS-TA injections with an average follow-up of 7.6 (range 3.0\u201314.9) months. Nine eyes (11.8%) developed OHT, four eyes (5.3%) had IOP &gt; 30 mmHg, and nine eyes (11.8%) had an IOP elevation of \u2265 10 mmHg above baseline at any point after their first injection. Eyes that developed OHT were treated with topical therapy (7 eyes, mean 1.9 agents, range 1\u20134 agents) or close observation (2 eyes). No eyes required incisional glaucoma surgery. Eyes with a history of glaucoma or OHT (7\/34, 20.1%) were more likely to develop OHT versus eyes with no history (2\/42, 4.8%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.03).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this real-world cohort, SCS-TA was associated with a low-incidence of OHT, consistent with clinical trial data. A history of glaucoma or OHT is a significant association for developing OHT after SCS-TA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004677","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T20:01:21Z","timestamp":1757966481000},"page":"220-228","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["REAL-WORLD INCIDENCE AND MANAGEMENT OF OCULAR HYPERTENSION AFTER SUPRACHOROIDAL TRIAMCINOLONE ACETONIDE INJECTION FOR MACULAR EDEMA IN NONINFECTIOUS UVEITIS"],"prefix":"10.1097","volume":"46","author":[{"given":"Saif A.","family":"Hamdan","sequence":"first","affiliation":[{"name":"Retina Service, Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Zafar","sequence":"additional","affiliation":[{"name":"Retina Service, Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie A.","family":"Nassur","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Yonekawa","sequence":"additional","affiliation":[{"name":"Retina Service, Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania;"},{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; and"},{"name":"The Vickie and Jack Farber Vision Research Center, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay E.","family":"Kuriyan","sequence":"additional","affiliation":[{"name":"Retina Service, Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania;"},{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; and"},{"name":"The Vickie and Jack Farber Vision Research Center, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Dunn","sequence":"additional","affiliation":[{"name":"Retina Service, Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania;"},{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; and"},{"name":"The Vickie and Jack Farber Vision Research Center, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Retina Service, Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania;"},{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hsu","sequence":"additional","affiliation":[{"name":"Retina Service, Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania;"},{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; and"},{"name":"The Vickie and Jack Farber Vision Research Center, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl D.","family":"Regillo","sequence":"additional","affiliation":[{"name":"Retina Service, Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania;"},{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunir J.","family":"Garg","sequence":"additional","affiliation":[{"name":"Retina Service, Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania;"},{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Xu","sequence":"additional","affiliation":[{"name":"Retina Service, Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania;"},{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Klufas","sequence":"additional","affiliation":[{"name":"Retina Service, Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania;"},{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3899-4456","authenticated-orcid":false,"given":"Jordan D.","family":"Deaner","sequence":"additional","affiliation":[{"name":"Retina Service, Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania;"},{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania; and"},{"name":"The Vickie and Jack Farber Vision Research Center, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260120","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.ophtha.2006.03.027","article-title":"Impact of macular edema on visual acuity in uveitis","volume":"113","author":"Lardenoye","year":"2006","journal-title":"Ophthalmology"},{"key":"R2-20260120","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1016\/j.ophtha.2015.07.036","article-title":"Outcome of treatment of uveitic macular edema: the multicenter uveitis steroid treatment trial 2-year results","volume":"122","author":"Tomkins-Netzer","year":"2015","journal-title":"Ophthalmology"},{"key":"R3-20260120","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.ophtha.2007.05.037","article-title":"Adverse events after intravitreal triamcinolone in patients with and without uveitis","volume":"114","author":"Galor","year":"2007","journal-title":"Ophthalmology"},{"key":"R4-20260120","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jcjo.2020.06.021","article-title":"Ocular hypertension following 40 mg sub-tenon triamcinolone versus 0.7 mg dexamethasone implant versus 2 mg intravitreal triamcinolone","volume":"55","author":"Kuley","year":"2020","journal-title":"Can J Ophthalmol"},{"key":"R5-20260120","doi-asserted-by":"crossref","first-page":"946","DOI":"10.18240\/ijo.2020.06.14","article-title":"Ocular hypertension and severe intraocular pressure elevation after posterior subtenon injection of triamcinolone acetonide for various diseases","volume":"13","author":"Yang","year":"2020","journal-title":"Int J Ophthalmol"},{"key":"R6-20260120","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","article-title":"Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) trial","volume":"126","author":"Thorne","year":"2019","journal-title":"Ophthalmology"},{"key":"R7-20260120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/IAE.0000000000002361","article-title":"Ocular hypertension after intravitreal injection of 2-mg triamcinolone","volume":"40","author":"Storey","year":"2020","journal-title":"Retina (Philadelphia, Pa)"},{"key":"R8-20260120","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.oret.2022.12.009","article-title":"A comparison of ocular complications after 0.7 mg dexamethasone implant versus 2 mg of intravitreal triamcinolone in vitrectomized eyes","volume":"7","author":"Wakabayashi","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"R9-20260120","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.survophthal.2012.08.003","article-title":"Intraocular pressure monitoring post intravitreal steroids: a systematic review","volume":"58","author":"Kiddee","year":"2013","journal-title":"Surv Ophthalmol"},{"key":"R10-20260120","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ophtha.2018.10.033","article-title":"Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results","volume":"126","author":"Jaffe","year":"2019","journal-title":"Ophthalmology"},{"key":"R11-20260120","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ajo.2022.10.008","article-title":"A 1-year retrospective case series of fluocinolone acetonide 0.18-mg injectable intravitreal implant in chronic uveitis","volume":"246","author":"Andrews","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"R12-20260120","first-page":"5063","article-title":"Suprachoroidal microinjection delivers triamcinolone acetonide to therapeutically-relevant posterior ocular structures and limits exposure in the anterior segment","volume":"54","author":"Edelhauser","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R13-20260120","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/17425247.2021.1867532","article-title":"Biomechanics of suprachoroidal drug delivery: from benchtop to clinical investigation in ocular therapies","volume":"18","author":"Hancock","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"key":"R14-20260120","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"key":"R15-20260120","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.ophtha.2024.04.014","article-title":"Leveraging real-world evidence to enhance clinical trials","volume":"131","author":"Borkar","year":"2024","journal-title":"Ophthalmology"},{"key":"R16-20260120","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/bjophthalmol-2020-318019","article-title":"Suprachoroidal CLS-TA for non-infectious uveitis: an open-label, safety trial (AZALEA)","volume":"106","author":"Henry","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R17-20260120","first-page":"1139","article-title":"Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA)","volume":"106","author":"Khurana","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R18-20260120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ceo.14024","article-title":"Suprachoroidal triamcinolone acetonide versus rescue therapies for the treatment of uveitic macular oedema: a post hoc analysis of peachtree","volume":"50","author":"Singer","year":"2022","journal-title":"Clin Exp Ophthalmol"},{"key":"R19-20260120","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000328630","article-title":"Steroid-induced iatrogenic glaucoma","volume":"47","author":"Razeghinejad","year":"2012","journal-title":"Ophthalmic Res"},{"key":"R20-20260120","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.1963.03060110088027","article-title":"Elevated intraocular pressure following corticosteroid eye drops","volume":"185","author":"Becker","year":"1963","journal-title":"JAMA"},{"key":"R21-20260120","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ophtha.2008.10.002","article-title":"Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection","volume":"116","author":"Roth","year":"2009","journal-title":"Ophthalmology"},{"key":"R22-20260120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0002-9394(14)73759-6","article-title":"The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis","volume":"120","author":"Helm","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"R23-20260120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1515\/sjecr-2016-0046","article-title":"The efficacy of a posterior sub-tenon\u2019s capsule triamcinolone injection in patients with non-infectious intermediate uveitis and posterior uveitis","volume":"18","author":"Andjelic","year":"2017","journal-title":"Serbian J Exp Clin Res"},{"key":"R24-20260120","doi-asserted-by":"crossref","first-page":"1916.e1","DOI":"10.1016\/j.ophtha.2005.06.009","article-title":"Outcome of intravitreal triamcinolone in uveitis","volume":"112","author":"Kok","year":"2005","journal-title":"Ophthalmology"},{"key":"R25-20260120","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","article-title":"Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis","volume":"129","author":"Lowder","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"R26-20260120","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/IAE.0000000000002901","article-title":"Uveitis treated with dexamethasone implant","volume":"41","author":"Mathis","year":"2021","journal-title":"Retina"},{"key":"R27-20260120","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1097\/IAE.0000000000003080","article-title":"Long-term incidence and risk factors of ocular hypertension following dexamethasone-implant injections: the SAFODEX-2 study","volume":"41","author":"Rezkallah","year":"2021","journal-title":"Retina"},{"key":"R28-20260120","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s40123-022-00525-8","article-title":"Real-life efficacy, safety, and use of dexamethasone intravitreal implant in posterior segment inflammation due to non-infectious uveitis (LOUVRE 2 study)","volume":"11","author":"Bodaghi","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R29-20260120","first-page":"459","article-title":"Suprachoroidal injection of triamcinolone acetonide suspension: ocular pharmacokinetics and distribution in rabbits demonstrates high and durable levels in the chorioretina","volume":"38","author":"Muya","year":"2022","journal-title":"J Ocul Pharmacol Ther"},{"key":"R30-20260120","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1097\/IAE.0000000000004132","article-title":"Suprachoroidal triamcinolone acetonide for refractory postoperative cystoid macula edema","volume":"44","author":"Momenaei","year":"2024","journal-title":"Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:00:25Z","timestamp":1768928425000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004677","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}